ACTC researchers presented updates at the Clinical Trials on Alzheimer’s Disease conference (CTAD) in Boston, Massachusetts and online. Ron Petersen received a lifetime achievement award and provided the first plenary keynote on a new hope in 2022 for therapeutics in Alzheimer’s. Reisa Sperling presented an update on the AHEAD study with the addition of blood based plasma screening. Jacobo Mintzer presented the design of the LIBBY study, Seth Gale presented the recommendations of handling research information in electronic medical records for preclinical AD research, and Rema Raman spoke on the critical role of biostatistics in Alzheimer’s therapeutic trial design and conduct. Sarah Walter presented recommendations from the ACTC Research Participant Advisory Board around the sharing of genetic and biomarker results in research, and Adam Boxer presented on the current status of tau interventions in AD and the plan for the ACTC Alzheimer’s Tau Platform, currently being reviewed at the NIA.